Payment overview · 2025
General Payments
$387.25
14 reported records · 11 companies
Healthcare provider profile · identity verified
Anderson Eng, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN FRANCISCO, CA · NPI 1831528363
Verified facts
What the public records show
CMS Open Payments records show Anderson Eng, D.O. received $387.25 in general payments during 2025 across 14 reported records.
Insmed, Inc. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $70.60 | 18.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $57.47 | 14.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.60 | 14.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.56 | 9.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.53 | 7.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.23 | 7.8% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.09 | 7.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.30 | 5.8% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.73 | 5.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.16 | 4.4% | 1 | 2025 |
| ModernaTX, Inc. | Unresolved — no canonical attribution shown | $16.98 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $387.25 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $70.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.60 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $29.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| mResvia Normalized: mresvia |
Drug | ModernaTX, Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 27 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 574 | 182 |
| Losartan Potassium | Losartan Potassium | 517 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 134 |
| Simvastatin | Simvastatin | 314 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 74 |
| Metformin Hcl | Metformin Hcl | 225 | 69 |
| Farxiga | Dapagliflozin Propanediol | 188 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 52 |
| Lisinopril | Lisinopril | 152 | 47 |
| Famotidine | Famotidine | 133 | 64 |
| Alendronate Sodium | Alendronate Sodium | 121 | 39 |
| Allopurinol | Allopurinol | 119 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 32 |
| Finasteride | Finasteride | 95 | 30 |
| Omeprazole | Omeprazole | 94 | 41 |
| Jardiance | Empagliflozin | 92 | 27 |
| Eliquis | Apixaban | 85 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 59 |
| Furosemide | Furosemide | 80 | 25 |
| Metformin Hcl Er | Metformin Hcl | 80 | 25 |
| Tradjenta | Linagliptin | 76 | 22 |
| Ezetimibe | Ezetimibe | 70 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 14 |
| Atenolol | Atenolol | 52 | 14 |
| Glipizide Er | Glipizide | 47 | 14 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 11 |
| Montelukast Sodium | Montelukast Sodium | 39 | 15 |
| Azelastine Hcl | Azelastine Hcl | 38 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Trazodone Hcl | Trazodone Hcl | 37 | 16 |
| Hydrocortisone | Hydrocortisone | 36 | 15 |
| Meloxicam | Meloxicam | 36 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 23 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 34 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 11 |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Gabapentin | Gabapentin | 30 | 12 |
| Lactulose | Lactulose | 29 | 11 |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | 12 |
| Ibuprofen | Ibuprofen | 26 | 22 |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 20 |
| Telmisartan | Telmisartan | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Prolia | Denosumab | 22 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 12 |
| Naproxen | Naproxen | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $387.25 · 14 records | Insmed, Inc. | Arikayce, CAPVAXIVE, EVENITY, GARDASIL 9, JARDIANCE, M-M-R II, MOUNJARO, PROLIA, PYRUKYND, VYNDAQEL, ZEPBOUND, ZTLido, mResvia | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error